MRK 016CAS# 783331-24-8 |
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- mGlu2 agonist
Catalog No.:BCC1745
CAS No.:1311385-32-6
- LY341495
Catalog No.:BCC1724
CAS No.:201943-63-7
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
- Dipraglurant
Catalog No.:BCC1531
CAS No.:872363-17-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 783331-24-8 | SDF | Download SDF |
| PubChem ID | 6918583 | Appearance | Powder |
| Formula | C17H20N8O2 | M.Wt | 368.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 10 mM in ethanol | ||
| Chemical Name | 3-[3-tert-butyl-2-[(2-methyl-1,2,4-triazol-3-yl)methoxy]pyrazolo[1,5-d][1,2,4]triazin-7-yl]-5-methyl-1,2-oxazole | ||
| SMILES | CC1=CC(=NO1)C2=NN=CC3=C(C(=NN32)OCC4=NC=NN4C)C(C)(C)C | ||
| Standard InChIKey | QYSYOGCIDRANAR-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | GABAA receptor inverse agonist selective for the α5-subtype (EC50 = 3 nM). Exhibits affinity at benzodiazepine binding site of recombinant human GABAA receptors (Ki values are 0.77 nM, 0.83 nM, 0.85 nM and 1.4 nM for α3-, α1-, α2-, and α5-containing respectively). Increases long-term potentiation (LTP) in mouse hippocampal slices. Exhibits no anxiogenic or proconvulsant activity. |
MRK 016 Dilution Calculator
MRK 016 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7145 mL | 13.5726 mL | 27.1451 mL | 54.2903 mL | 67.8629 mL |
| 5 mM | 0.5429 mL | 2.7145 mL | 5.429 mL | 10.8581 mL | 13.5726 mL |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7145 mL | 5.429 mL | 6.7863 mL |
| 50 mM | 0.0543 mL | 0.2715 mL | 0.5429 mL | 1.0858 mL | 1.3573 mL |
| 100 mM | 0.0271 mL | 0.1357 mL | 0.2715 mL | 0.5429 mL | 0.6786 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- H-D-1-Nal-OH
Catalog No.:BCC3281
CAS No.:78306-92-0
- 7-Ethylcamptothecin
Catalog No.:BCN2480
CAS No.:78287-27-1
- Ecliptasaponin A
Catalog No.:BCN3843
CAS No.:78285-90-2
- Nepafenac
Catalog No.:BCC1258
CAS No.:78281-72-8
- Hydroxysafflor yellow A
Catalog No.:BCN1049
CAS No.:78281-02-4
- [Orn5]-URP
Catalog No.:BCC5985
CAS No.:782485-03-4
- Paroxetine HCl
Catalog No.:BCC5054
CAS No.:78246-49-8
- 20(S)-Ginsenoside Rh2
Catalog No.:BCN1070
CAS No.:78214-33-2
- Nirtetralin
Catalog No.:BCN3755
CAS No.:78185-63-4
- YM155
Catalog No.:BCC2251
CAS No.:781661-94-7
- 4-Hydroxyisoleucine
Catalog No.:BCN1211
CAS No.:781658-23-9
- CDPPB
Catalog No.:BCC7610
CAS No.:781652-57-1
- MLN120B
Catalog No.:BCC1772
CAS No.:783348-36-7
- PCI-24781 (CRA-024781)
Catalog No.:BCC2155
CAS No.:783355-60-2
- Nocamycin I
Catalog No.:BCN1845
CAS No.:78339-49-8
- Pyranojacareubin
Catalog No.:BCN7429
CAS No.:78343-62-1
- MY-5445
Catalog No.:BCC6645
CAS No.:78351-75-4
- 1,7-Dihydroxy-2,3-dimethoxyxanthone
Catalog No.:BCN7523
CAS No.:78405-33-1
- Milrinone
Catalog No.:BCC4374
CAS No.:78415-72-2
- Trequinsin hydrochloride
Catalog No.:BCC7333
CAS No.:78416-81-6
- 5,7,3'-Trihydroxy-6,4',5'-trimethoxyflavone
Catalog No.:BCN1353
CAS No.:78417-26-2
- RGB-286638
Catalog No.:BCC5519
CAS No.:784210-87-3
- RGB-286638 free base
Catalog No.:BCC5520
CAS No.:784210-88-4
- Deacetyltaxol
Catalog No.:BCN2820
CAS No.:78432-77-6
Administration of the inverse benzodiazepine agonist MRK-016 rescues acquisition and memory consolidation following peripheral administration of bacterial endotoxin.[Pubmed:25823763]
Behav Brain Res. 2015 Jul 15;288:50-3.
Recent evidence suggests that inflammation-induced decrements in cognitive function can be mitigated via manipulation of excitatory or inhibitory transmission. We tested the ability of the inverse benzodiazepine agonist, MRK-016 (MRK) to protect against LPS-induced deficits in memory acquisition and consolidation, using a contextual fear conditioning (CFC) paradigm. In Experiment One, mice received lipopolysaccharide (LPS) and/or MRK injections prior to CFC training, and were then tested 24h after training. In Experiment Two, animals received similar treatment injections immediately after training, and were tested 24h later. Additionally, hippocampal samples were collected 4h after LPS injections and immediately after testing, to evaluate brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) mRNA expression. Results indicate that MRK can protect against LPS-induced learning/memory decrements in both paradigms. We also found, in both paradigms, that animals treated with LPS/Saline expressed significantly less BDNF mRNA when compared to Saline/Saline-treated animals 4h after LPS administration, but that MRK did not restore BDNF expression levels. Further, treatment administrations had no effect on IGF-1 mRNA expression at any collection time-point. In summary, MRK-016 can protect against LPS-induced deficits in memory acquisition and consolidation, in this hippocampus-dependent paradigm, though this protection occurs independently of recovery of BDNF expression.
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)- pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.[Pubmed:19704033]
J Pharmacol Exp Ther. 2009 Nov;331(2):470-84.
3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)- pyrazolo[1,5-d][1,2,4]triazine (MRK-016) is a pyrazolotriazine with an affinity of between 0.8 and 1.5 nM for the benzodiazepine binding site of native rat brain and recombinant human alpha1-, alpha2-, alpha3-, and alpha5-containing GABA(A) receptors. It has inverse agonist efficacy selective for the alpha5 subtype, and this alpha5 inverse agonism is greater than that of the prototypic alpha5-selective compound 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-hdyl)methyloxy]-1,2,4-tria zolo[3,4-a]phthalazine (alpha5IA). Consistent with its greater alpha5 inverse agonism, MRK-016 increased long-term potentiation in mouse hippocampal slices to a greater extent than alpha5IA. MRK-016 gave good receptor occupancy after oral dosing in rats, with the dose required to produce 50% occupancy being 0.39 mg/kg and a corresponding rat plasma EC(50) value of 15 ng/ml that was similar to the rhesus monkey plasma EC(50) value of 21 ng/ml obtained using [(11)C]flumazenil positron emission tomography. In normal rats, MRK-016 enhanced cognitive performance in the delayed matching-to-position version of the Morris water maze but was not anxiogenic, and in mice it was not proconvulsant and did not produce kindling. MRK-016 had a short half-life in rat, dog, and rhesus monkey (0.3-0.5 h) but had a much lower rate of turnover in human compared with rat, dog, or rhesus monkey hepatocytes. Accordingly, in human, MRK-016 had a longer half-life than in preclinical species ( approximately 3.5 h). Although it was well tolerated in young males, with a maximal tolerated single dose of 5 mg corresponding to an estimated occupancy in the region of 75%, MRK-016 was poorly tolerated in elderly subjects, even at a dose of 0.5 mg, which, along with its variable human pharmacokinetics, precluded its further development.
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.[Pubmed:15537339]
J Med Chem. 2004 Nov 18;47(24):5829-32.
(3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine (13) has been identified as a functionally selective, inverse agonist at the benzodiazepine site of GABA(A) alpha5 receptors. 13 is orally bioavailable, readily penetrates the CNS, and enhances performance in animal models of cognition. It does not exhibit the convulsant, proconvulsant, or anxiogenic activity associated with nonselective GABA(A) inverse agonists.
